Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Healthstream (HSTM) Research & Development (2016 - 2025)

Healthstream (HSTM) has disclosed Research & Development for 16 consecutive years, with $14.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development rose 16.35% to $14.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $51.0 million, a 4.28% increase, with the full-year FY2025 number at $51.0 million, up 4.28% from a year prior.
  • Research & Development was $14.8 million for Q4 2025 at Healthstream, up from $12.1 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $14.8 million in Q4 2025 to a low of $9.5 million in Q1 2021.
  • A 5-year average of $11.6 million and a median of $11.7 million in 2022 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: surged 32.01% in 2021, then fell 5.01% in 2023.
  • Healthstream's Research & Development stood at $11.5 million in 2021, then increased by 3.08% to $11.8 million in 2022, then grew by 1.04% to $11.9 million in 2023, then increased by 6.3% to $12.7 million in 2024, then rose by 16.35% to $14.8 million in 2025.
  • Per Business Quant, the three most recent readings for HSTM's Research & Development are $14.8 million (Q4 2025), $12.1 million (Q3 2025), and $12.1 million (Q2 2025).